<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141553">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01258205</url>
  </required_header>
  <id_info>
    <org_study_id>20090519</org_study_id>
    <nct_id>NCT01258205</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Mild to Severe Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of AMG 139 following
      multiple intravenous (IV) or subcutaneous (SC) dose administration in healthy subjects and
      in subjects with mild to severe Crohn's disease (CD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety &amp; tolerability: treatment-emergent AEs including clinically significant changes in physical examinations, safety lab tests, ECG, vital signs, or immunogenicity to AMG 139</measure>
    <time_frame>36 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterization of the pharmacokinetic (PK) parameters (AUCtau, Cmax, tmax) for AMG 139 after multiple IV and SC dose administrations in healthy subjects and subjects with mild to severe CD</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose level of AMG 139 administered as a multiple doses IV in subjects with mild-severe Crohn's disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three dose levels of AMG 139 administered as a multiple doses IV or SC in healthy subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 139</intervention_name>
    <description>Four dose levels of AMG 139 administered as multiple doses IV or SC in healthy volunteers (Part A) and subjects with moderate-severe Crohn's disease (Part B).</description>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Part A - Healthy Subjects:

          -  Healthy male or female of non-reproductive potential subjects between 18 to 45
             years-of-age

          -  Body mass index (BMI) between 18 and 32 kg/m2

          -  Normal or clinically acceptable physical examination, clinical laboratory values, and
             ECG

          -  Additional inclusion criteria apply

        Part B - Crohn's Subjects:

          -  Male or female subjects with CD between 18 to 55 years-of-age

          -  Body mass index (BMI) between 18 and 32 kg/m2

          -  Normal or clinically acceptable physical examination (PE), clinical laboratory
             values, and ECG; clinically acceptable PE includes evidence of mild to severe CD

          -  Diagnosis of ileal or ileo-colonic CD for a minimum of 6 months

          -  Mild to severe CD defined by a Crohn's Disease Activity Index (CDAI) score equal to
             or greater than 180 and equal to or less than 450

          -  Elevated fecal calprotectin and CRP

          -  Additional inclusion criteria apply

        Exclusion Criteria:

        Parts A - Healthy Subjects:

          -  History or evidence of a clinically significant disorder (including psychiatric),
             condition or disease that would pose a risk to subject safety or interfere with the
             study evaluation, procedures or completion;

          -  Recent or on-going infection(s)

          -  Underlying condition(s) that predisposes the subject to infections

          -  History of malignancy of any type

          -  Additional exclusion criteria apply

        Part B only - Crohn's Subjects:

          -  History or evidence of a clinically significant disorder (including psychiatric),
             condition or disease that would pose a risk to subject safety or interfere with the
             study evaluation, procedures or completion;

          -  Recent or on-going infection(s)

          -  Underlying condition(s) that predisposes the subject to infections

          -  History of malignancy of any type

          -  Additional exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prahran</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 13, 2015</lastchanged_date>
  <firstreceived_date>December 9, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amgen</keyword>
  <keyword>AMG 139</keyword>
  <keyword>Crohn's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
